- Home
- SOPH vs INBX Comparison
SOPH vs INBX Comparison
Compare SOPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 1.1B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SOPH | INBX |
|---|---|---|
| Price | $4.78 | $78.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 202.5K | 153.9K |
| Earning Date | 01-01-0001 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | $18.48 | $563.00 |
| Revenue Next Year | $16.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.58 | $10.81 |
| 52 Week High | $5.70 | $94.57 |
Technical Indicators
Market Signals| Indicator | SOPH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 51.22 |
| Support Level | $4.73 | $74.77 |
| Resistance Level | $5.03 | $84.50 |
| Average True Range (ATR) | 0.29 | 5.47 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 24.51 | 39.09 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.